What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance.
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
Overview
Howard W. Robin, President & CEO of Nektar Therapeutics (NASDAQ:NKTR), disclosed the sale of 20,000 shares in multiple open-market transactions on June 16 and June 17, 2026, for a total value of approximately $1.22 million, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($60.75); post-transaction value based on June 17, 2026 market close ($60.75).
Details
* 1-year price change calculated using June 17th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
